Phison's Pascari Enterprise Storage Honored with COMPUTEX Best Choice Golden Award for Breakthrough 245.76 TB Capacity
21.5.2026 08:30:00 CEST | Business Wire | Press Release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, today announced that its Pascari D206V PCIe Gen5 data center SSD has received the prestigious COMPUTEX Best Choice Golden Award, recognizing the next generation of innovation in ultra-high-capacity enterprise storage for AI and modern data center infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520865786/en/
Pascari D206V Wins COMPUTEX Best Choice Golden Award in 2026
The Pascari D206V is designed to address the growing industry challenge of efficiently scaling storage capacity for AI, cloud and data-intensive workloads without increasing operational complexity or infrastructure costs. Delivering up to 245.76 TB in a single U.2 PCIe Gen5 SSD, the D206V enables hyperscale and enterprise customers to significantly increase storage density while reducing rack footprint, power consumption and total data center OPEX.
“We are honored to receive the COMPUTEX Best Choice Golden Award and thank the organizers and judging panel for this recognition,” said K.S. Pua, Founder and CEO of Phison Electronics. “As AI and HPC deployments increase worldwide, organizations face growing demands for storage infrastructure that delivers greater density, efficiency, reliability and performance. The Pascari D206V was purpose-built for this new era of data center scale to help organizations store more, scale faster and optimize operational efficiency. This award reinforces Phison’s commitment to enable organizations to innovate through their data.”
Key Pascari D206V features and benefits include:
- Ultra-high storage density: Up to 245.76 TB in a single U.2 SSD enables organizations to consolidate infrastructure and maximize storage capacity per rack.
- Reduced data center OPEX: Up to an 8:1 capacity advantage over traditional HDD-based cold storage environments1 helps lower power consumption, cooling demands, rack space usage and overall operational costs.
- Read-optimized Gen5 performance: Up to 14 GB/s sequential read speeds and 2,625K million random read IOPS accelerate access to large-scale AI and enterprise datasets.
- Enterprise-grade reliability and protection: Features including dual-port connectivity, power loss protection (PLP), AES-256 encryption, TCG Opal 2.0, NVMe-MI management, 128 namespaces and end-to-end data path protection help ensure data integrity, security and system resiliency.
- OCP-aligned compatibility: Supports OCP Datacenter NVMe SSD specifications for streamlined deployment across hyperscale and open compute environments.
- Flexible deployment options: Available in U.2 for 245.76 TB capacity and E1.L, E3.L and E3.S form factors for all other D206V capacities to optimize density, thermal efficiency and scalability across diverse infrastructure architectures.
To explore more innovations, visit Phison’s COMPUTEX showcase, including the Pascari D206V and its latest AI storage innovations, at TaiNEX Hall 1, Booth M0411a. To learn more about the Pascari D206V, visit the Phison website.
About Phison Electronics
Phison Electronics is a global leader in NAND flash controllers and storage solutions, powering more than one in every five SSDs shipped worldwide. Phison has grown into a multi-billion-dollar company with over 4,500 employees—70% of which are dedicated to R&D – and more than 2,000 patents. The company’s innovations include aiDAPTIV+, an award-winning AI solution for affordable LLM training and inferencing on-premises, and Pascari, a portfolio of ultra-high-performance enterprise SSDs purpose-built for data-intensive workloads across AI, cloud, and hyperscale data centers.
Phison, the Phison design, the Phison logo are registered trademarks or trademarks of Phison Electronics or its affiliates in the US and/or other countries. All other marks are the property of their respective owners. Product specifications subject to change without notice. Pictures shown may vary from actual products.
Disclaimer: Many of the products and features mentioned are still in development and will be made available as they are finalized. The timeline for their release is dependent on the ongoing development and market and is subject to change.
©2026 Phison Electronics or its affiliates. All rights reserved.
1 All values provided are based on estimation. 1 TB = 1012 bytes. Sequential Performance is based on FIO on Linux, 128KB data size, with QD=32, 1 job. Random Performance is based on FIO on Linux, random read 4KB data size, random write 16KB data size, QD=128, 8 jobs. Latency is measured with random workloads based on FIO on Linux, 4KB data size, QD=1, 1 job. Power consumption (average RMS) is measured during the sequential read/write and random read/write operations performed by iometer. The results of DWPD are obtained in compliance with JESD219A standards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520865786/en/
Contacts
PHISON Spokesperson
Antonio Yu
TEL: +886-37-586-896 #10019
Mobile: +886-979-105-026
Email: antonioyu@phison.com
PHISON Deputy Spokesperson
Kuo-Ting Lu
TEL: +886-37-586-896 #26022
Mobile: +886-979-075-330
Email: kuoting_lu@phison.com
PHISON and PASCARI enterprise product inquiries:
sales@phison.com
sales@phisonenterprise.com
PHISON and PASCARI enterprise media inquiries:
Lynn Kelly
Lynn_kelly@phison.com
press_americas@phison.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom